Patents Assigned to ZymoGenetics, Inc.
  • Anti-human IL-21 monoclonal antibodies
    Patent number: 8124089
    Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: February 28, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
  • Antibody to human Zcyto10 polypeptide
    Patent number: 8124739
    Abstract: A mammalian cytokine-like polypeptide, called Zcyto10, polynucleotides encoding the same, antibodies which specifically bind to the polypeptide, and anti-idiotypic antibodies which bind to the antibodies. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets.
    Type: Grant
    Filed: September 27, 2010
    Date of Patent: February 28, 2012
    Assignee: Zymogenetics, Inc.
    Inventors: Darrell C. Conklin, Betty A. Haldeman, Angelika Grossmann
  • Methods of treatment using anti-IL-22RA antibodies
    Patent number: 8124088
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: February 28, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret Dow Moore
  • Methods of purifying zsig33
    Patent number: 8124356
    Abstract: The present invention relates to a method of forming a peptide-receptor complex with zsig33 polypeptides and their receptors as well as antibodies. Methods of modulating gastric contractility, nutrient uptake, growth hormones, the secretion of digestive enzymes and hormones, and/or secretion of enzymes and/or hormones in the pancreas are also included.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: February 28, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Darrell C. Conklin
  • Murine zcytor17 ligand polynucleotides
    Patent number: 8124378
    Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: February 28, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Jane A. Gross, Angela K. Hammond, Rolf E. Kuestner
  • Cytokine Protein Family
    Patent number: 8124065
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-? at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: February 28, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Brian A. Fox, Kevin M. Klucher, David W. Taft, Wayne Kindsvogel
  • Method of use of cytokine ZALPHA11 ligand
    Patent number: 8110180
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: February 7, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Methods for detecting modulators of cytokine receptor zalpha11
    Patent number: 8110372
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zalpha11, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zalpha11, are located on chromosome 16, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: March 3, 2011
    Date of Patent: February 7, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Darrell C. Conklin, Julia E. Novak, Angela K. Hammond
  • Methods of antagonizing signal transduction in dorsal root ganglion cells
    Patent number: 8105591
    Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: January 31, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Yue Yao, Janine Bilsborough
  • Methods of treating inflammation in neuronal tissue
    Patent number: 8105590
    Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: January 31, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Yue Yao, Janine Bilsborough
  • Human cytokine receptor
    Patent number: 8101381
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides polynucleotides, vectors, cells, and methods of production related to a new human cytokine receptor designated as “Zcytor16.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: January 24, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen, Steven D. Hughes
  • Soluble IL-17RCx4 and fusion proteins thereof
    Patent number: 8093355
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RC is a common receptor for IL-17A and IL-17F. The present invention includes methods of using a soluble IL-17RC receptor, IL-17RCx4 for treating inflammation.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: January 10, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Rolf E. Kuestner, Zeren Gao, Steven D. Levin, Mark W. Rixon
  • Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use
    Patent number: 8084426
    Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: December 27, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Emma E. Moore, Jeff L. Ellsworth
  • Trimerizing polypeptides
    Patent number: 8084230
    Abstract: The present invention relates to a method of preparing a trimeric protein comprising culturing a host cell transformed or transfected with an expression vector encoding a fusion protein comprising a ZymoZipper (ZZ) domain and a heterologous protein. In one embodiment, the heterologous protein is a membrane protein, the portion of the heterologous protein that included in the fusion protein is the extracellular domain of that protein, and the resulting fusion protein is soluble. In another embodiment of the present invention, the ZZ domain is derived from the transmembrane (TM) subunit of a virus envelope protein or another heptad repeat containing gene of a virus genome. The method can be used to produced homo- and hetero-trimeric proteins. The present invention also encompasses DNA molecules, expression vectors, and host cells used in the present method and fusion proteins produced by the present method.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: December 27, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Margaret Dow Moore, Brian A. Fox
  • Soluble IL-17RA/RC fusion proteins and related methods
    Patent number: 8084231
    Abstract: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: December 27, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Steven D. Levin, Mark W. Rixon, Gao Zeren
  • Stabilized thrombin compositions
    Patent number: 8071090
    Abstract: Stabilized thrombin compositions, processes for preparing them, and kits comprising them are disclosed. The compositions comprise thrombin, a bacteriostatically effective amount of benzyl alcohol or chlorobutanol, and 0.10%-5.0% (w/v) sucrose in aqueous solution. The compositions are stable when stored at 2° C.-8° C. for four weeks or more.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: December 6, 2011
    Assignee: Zymogenetics, Inc.
    Inventors: Richard I. Senderoff, Shan Jiang
  • Method for activating prethrombin-1
    Patent number: 8062876
    Abstract: Methods for converting prethrombin-1 to thrombin are disclosed. An aqueous solution of prethrombin-1 is applied to oscutarin-C immobilized on a solid support so as to provide from 500 mg to 4000 mg of prethrombin-1 per mL of the solid support and a contact time between the prethrombin-1 and the oscutarin-C of from 1.8 to 3.5 minutes. The resulting active thrombin may be captured on an ion exchange chromatography medium or an affinity chromatography medium.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: November 22, 2011
    Assignee: Zymogenetics, Inc.
    Inventors: Robert W. Mallett, Christopher J. Stenland, Jonathon C. Boone, John W. Forstrom, Karen S. De Jongh
  • Growth factor homolog ZVEGF3
    Patent number: 8052976
    Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residues 235-345 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
    Type: Grant
    Filed: April 22, 2008
    Date of Patent: November 8, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Zeren Gao, Charles E. Hart, Christopher S. Piddington, Paul O. Sheppard, Kimberty E. Shoemaker, Debra G. Gilbertson, James W. West
  • Method of suppressing or reducing IL-TIF-induced inflammation, or treating associated conditions thereof, using Zcytor16
    Patent number: 8034784
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16” and uses thereof.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: October 11, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen
  • Methods of determining dose of IL-31 agonist to treat pulmonary inflammation
    Patent number: 8029775
    Abstract: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: October 4, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Janine M. Bilsborough, Eric M. Chadwick, Sherri L. Mudri